Medical Marijuana, Inc. (OTC: MJNA) (“the Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM) has begun manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC).
| SAN DIEGO, Sept. 12, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (“the Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM) has begun manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). The chewing gum, manufactured through AXIM’s contract manufacturer, Eurofins Amatsigroup in Belgium, is intended for use in AXIM’s upcoming clinical studies on cannabis as a treatment for chemotherapy-related symptoms. According to the Center for Disease Control and Prevention (CDC), about 650,000 cancer patients in the U.S. receive chemotherapy each year with an average cost of $100,000 per patient per year. Symptoms that many chemotherapy patients experience include a weakened immune system, pain, nausea, vomiting, and diarrhea. “Medical Marijuana, Inc. has always supported the efforts of AXIM to conduct research that allows them to provide those in need with innovative delivery mechanisms,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We look forward to the findings of AXIM’s upcoming dronabinol chewing gum studies and understanding how it may help those undergoing chemotherapy.” In the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and FDA-approved capsules containing dronabinol – and later provide evidence that the dronabinol chewing gum can serve as an alternative to orally ingested dronabinol for the treatment of symptoms associated with chemotherapy. “Our unique delivery mechanism allows our products to enter the body through the oral mucosa, bypassing the liver and allowing for greater bioavailability,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “Through these studies, we want to show the bioequivalence of our dronabinol gum to already FDA-approved synthetic THC products so that we can offer it to chemotherapy patients through our proven and convenient delivery mechanism.” For more information about AXIM and its clinical product pipeline, please visit www.aximbiotech.com. To learn more about Medical Marijuana, Inc., visit https://www.medicalmarijuanainc.com/. About Medical Marijuana, Inc. To see Medical Marijuana, Inc.'s corporate video, click here. Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop. About AXIM® Biotechnologies AXIM’s flagship product, MedChew® with dronabinol, is planned to undergo a bioequivalence study in the near future to fast track through FDA as an alternative delivery mechanism. For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE LEGAL DISCLOSURE CONTACT: Investor Relations Contact:
SOURCE Medical Marijuana, Inc. | ||
Company Codes: OTC-PINK:MJNA, OTC-PINK:AXIM |
View original content:
